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Treatment of l-O-[‘H]alkyl-2-acyl-phosphatidylcholine-prela~led human polyrnorphonuclear leukocytes (PMNs) with staurosporine (50 nM to 
1 PM) induced a time- and concentration-dependent generation of tritiated phosphatidic acid (PA), reaching approximately 225% of the control 
value at 15-20 min. In the presence of ethanol, staurosporine induced a production of phosphatidylethanol (PEt) reaching, 250% of control values, 
and partial inhibition of PA production, consistent with PLD activation. The amount of ether-linked acylglycerol (EAG) was weakly enhanced 
(29%) after 5 min of PMN treatment; longer treatment resulted in no significant EAG production, suggesting a possible late inhibition of PA 
hydrolase activity. Staurosporine concentrations that induced an elevation in PA completely depressed protein kinase C (PKC) activity in both 
soluble and particulate cell fractions, suggesting that PLD activation may occur independently from PKC activation. PLD may thus represent a 
potential cellular target for staurosporine action. 
Staurosporine; Phospholipase D; Protein kinase C; Neutrophil 
1. INTRODUCTION 
Phospholipase D (PLD) catalyzes the hydrolysis of 
phosphatidylcholine (PC) to phosphatidic acid (PA), 
which is a precursor of diacylglycerol (DAG) and ether- 
linked-acylglycerol (EAG). Stimulation of the PLD 
pathway in various cell types has been proposed to be 
involved in cellular responses [l-d]. In human polymor- 
phonuclear leukocytes (PMN) stimulated by formyl 
peptides, the PLD pathway represents a major source 
of PA and diglycerides [5,6]. In the presence of ethanol, 
PLD also catalyzes a transphosphatidylation reaction 
[7] which transforms PC into a non-physiological me- 
tabolite, phosphatidylethanol (PEt). The mechanism 
PLD activation is believed to occur through both pro- 
tein kinase C (PKC)-dependent and independent proc- 
esses. 
Staurosporine, a microbial alkaloid from streptomy- 
ces species, is a potent PKC inhibitor [8] which inter- 
feres with the binding of ATP to the catalytic domain 
of PKC [9]. Staurosporine has been largely used to in- 
vestigate the role of PKC in signal transduction path- 
ways and has led to some conflicting data. In many cell 
types, the activation of PLD by phorbol esters is inhib- 
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ited by kinase inhibitors including staurosporine [lO- 
151, a finding consistent with the involvement of PKC 
in PLD activation. In lymphocytes [16] and mast cells 
[17], PLD activation by phorbol esters is not altered by 
staurosporine. A staurosporine-induced enhancement 
of PLD activation in phorbol ester-treated rabbit plate- 
let membrane [18] and in formyl peptide-stimulated 
polymorphonuclear leukocytes [ 191 has also been re- 
ported. The present study shows that staurosporine 
concentrations that block PKC activation promotes 
stimulation of PLD in human PMNs. PLD appears as 
a potential cellular target for regulation by stauro- 
sporine. 
2. MATERIALS AND METHODS 
2.1. Reagents 
l-O-[3H]octacedyI-sn-gIycerophosphocholine (sp cific activity 169 
Ci/mmol) was from Amersham (les Ullis, France), staurosporine from 
Kamiya Biomedical Co. (Thousands Oaks, CA), precoated silica gel 
G plates (0.25 mm thick) from Merck (Nogent, France) and other 
reagents from Sigma Co. (St Louis, MO). 
2.2. PMN preparation 
Human venous blood, heparinized at 10 units/ml, was obtained 
from healthy volunteers. PMNs were isolated by one-step centrifuga- 
tion of whole blood on a cushion of a mixture of Ficoll and Hypaque 
(monopoly resolving medium, from Flow Laboratories, Puteaux, 
France), as previously described 120,211. The purified PMNs (97%) 
were subjected to hypotonic lysis, washed and resuspended in HBSS 
(pH 7.4). 
2.3. Preparation of labeled PMNs and lipid analysis 
PMNs (2 x 10’ cells/ml) were incubated in calcium-free HBSS con- 
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taining 10 mM HEPES, 0.1% BSA and S,&i/ml I-O-[‘Hloctadecyl-sn- 
glycero-3-phophocholine for one hour [l 11. Lipids were extracted as 
described in (221 and aliquots of the chloroform extracts were dried 
under N, and spotted onto TLC silicagel plates. Analysis of lipids by 
TLC with a solvent system consisting of chloroform/methanol/acetic 
acid/H,0 (75:48:12.5:3.5) confirmed that approximately 85% of the 
cellular radioactivity was found in I-O-alkyl-2-acyl-3-glycero- 
phosphocholine under these conditions [l 11. Aliquots of 3 x IO6 la- 
beled PMNs in 400 ~1 of HBSS were prewarmed for 5 min at 37°C 
and treated in the presence or absence of staurosporine. In some 
experiments, 1% ethanol was added to the medium 3 min before the 
addition of staurosporine. Reactions were terminated by adding 1.5 
ml of chloroform/methanol/acetic a id (100:200:2); lipids were ex- 
tracted and separated by TLC. A solvent system consisting of chloro- 
form/methanol/acetic a id (65:15:2) was used to resolve phosphatidic 
acid (I?< = 0.42) from PEt (R, = 0.62), as described elsewhere Ill]. 
I-O-Alkyl-2-acyl-glycerol (EAG; RI = 0.62) was separated using chlo- 
roform/methanol/acetic a id (98:2: l), as reported [23]. 
2.4. Protein kinase C assay 
PMNs were treated in the absence or presence of 100 and 500 nM 
staurosporine for 15 min at 37 “C, then were washed and spun down. 
Pellets were resuspended in lysis buffer containing 20 mM Tris, pH 
7.5, 0.25 mM sucrose, 2 mM PMSF, 0.01% leupeptine. 50 mM 2- 
mercaptoethanol, 2 mM EDTA and 5 mM EGTA and disrupted by 
sonication. Postnuclear supernatants were spun down at 100,000 x g 
for one hour and the soluble fraction separated from pellets (particu- 
late fraction). Pellets were homogeneized by sonication in lysis buffer 
containing 0.1% Triton and centrifuged at 100,000 x g for 60 min at 
4qC. Tthe supematant, referred to as the particulate fraction. PKC 
activity was assayed by measuring the incorporation of j2P into histone 
[24]. Briefly, the reaction mixture contained 10 mM MgCl,, 1 mM 
CaCl,, 2 pg of phosphatidylserine, 0.1 pg of 1,2-sn-diolein, 20 pug of 
histone. 10 ,uM ATP (containing 0.5 ,UZi of [3’P]ATP) and 2 pg of 
soluble or elutable protein in 100 ~1 of Tris-HCl 20 mM. pH 7.5. 
Reactions were started with ATP, allowed to run for 10 min at 30°C 
and stopped by the addition or 400 ,~l of ice-cold 20% trichloracetic 
acid followed by 100 ~1 of BSA (2.5 mg/ml) as carrier. Precipitates 
were washed after dissolution of the pellet in 0.5 N NaOH and quan- 
tified by scintillating counting. PKC activity is expressed in pmoles of 
‘*P incorporated per min per mg protein and was calculated by sub- 
tracting the activity measured in the absence of calcium, phosphati- 
dylserine and diolein from that measured in their presence. No signif- 
icant PKC activity was detected in the non eluable particulate fraction 
and the PKC activity of the particulate fraction is threrefore that 
found in the elutable fraction. 
2.5. Statistical analysrs 
Statistically significant differences between experiments performed 
m the presence and absence of staurosporine were determined using 
the paired Student’s r-test with a threshold of P < 0.05. 
3. RESULTS AND DISCUSSION 
PMNs were first labeled in l-O-[3H]octadecyl-2-acyl- 
sn-glycero-3-phosphocholine and then incubated in the 
presence of staurosporine (50 nM to 1 PM) for 15 min 
at 37°C. Under these conditions, staurosporine induced 
a concentration-dependent rise in the basal amount of 
tritiated PA, which reached a maximal measured value 
of approximately 225% (P < 0.001) of the control value 
(no staurosporine treatment), as shown in Fig. 1. The 
staurosporine-induced PA elevation was rapid, reach- 
ing 21% (P < 0.05) of control value at 5 min of cell 
treatment, and plateaued at 15-20 min (Fig. 2). The 
increase in PA levels may be interpreted as being due to 
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Fig. 1. Staurosporine stimulates phosphatidic acid (PA) production in 
PMNs. PMNs prelabeled in alkyl-PC were treated in the absence 
(control) or presence of various concentrations of staurosporine for 
15 min. PA production was evaluated after extraction of lipids and 
separation by TLC. Results are the means of 3 experiments and are 
expressed as % PA production relative to controls (not treated by 
staurosporine; 4410 + 444 dpmI3 x lo6 PMNs). 
activation of PLD and/or inhibition of PA degradation. 
Measurement of ether-linked acylglycerol (EAG), the 
dephosphorylated form of PA, showed that EAG pro- 
duction reached approximately 29% (P < 0.05) of con- 
trol values by 5 min, whereas longer periods of PMN 
treatment resulted in no statistically significant EAG 
production (Fig. 2). This late decrease in EAG produc- 
tion relative to that in PA raises the possibility that 
staurosporine inhibited PA hydrolase activity. To deter- 
mine whether the PA elevation was due to PLD activa- 
tion, we measured phosphatidylethanol (PEt), a rela- 
tively inert metabolite widely accepted as marker of 
PLD activation. In the presence of 1% ethanol, stauro- 
sporine (0.1 to 1 PM) induced a concentration-depend- 
ent production of PEt, with partial inhibition of the PA 
elevation (Fig. 3). The maximal measured potentiation 
of the PEt level reached approximately 250% 
(P < 0.001) of control values. However, the enhance- 
ment of PEt and PA represented less than 1% of the 
labeling of the PC pool; no significant decrease in the 
labeled PC pool was thus observed (results not shown). 
These data are consistent with an activation of PLD in 
staurosporine-treated PMNs. 
The activation of PLD by phorbol esters in various 
cell types is believed to occur through a PKC-dependent 
process since these agents bind to and activate PKC 
[25]. As staurosporine is a potent PKC inhibitor, we 
determined the degree of PKC inhibition when PMNs 
were treated with staurosporine. After incubation with 
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100 and 500 nM staurosporine for 15 min, PMNs were 
washed and fractionated into soluble and particulate 
fractions. The activation of PKC in both fractions, as 
assessed by histone phosphorylating activity, was 
strongly depressed (Table I), suggesting that PLD acti- 
vation by staurosporine is not related to PKC activa- 
tion. 
The ability of staurosporine to elevate of PA in rest- 
ing PMNs is a novel aspect of its biological activating 
properties. The PA elevation appeared to be mainly due 
to PLD activation, as evidenced by the use of ethanol, 
which permits the accumulation of PEt by inhibiting PA 
formation (Fig. 3). These data are consistent with the 
concept that the activated PLD in staurosporine-treated 
PMNs catalyzes both the hydrolysis of PC to PA and 
the transphosphatidylation reaction. The enhancement 
of PA level could also be explained, in part, by inhibi- 
tion of PA phosphohydrolase, as suggested by the weak 
generation of EAG relative to that of PA (Fig. 2). Alter- 
natively, the PA elevation could result from a potentia- 
tion of diglyceride kinase. Such a possibility has been 
reported with an endogenous PKC inhibitor, sphingo- 
sine [26]. 
Activation of PLD in many cell types has been sug- 
gested to be mediated through both PKC-dependent 
and independent processes, on the basis of the observa- 
tion that kinase inhibitors such as staurosporine, K252a 
and H-7 only partially prevent PLD activation. With 
certain cells, the use of kinase inhibitors has led to con- 
flicting data. For example, in lymphocytes, stauro- 
sporine failed to alter PMA-induced PLD activation 
[ 161. In mast cells, differential alteration of PLD activa- 
tion according to the stimulant used has been reported: 
antigen-induced PA production was inhibited, whereas 
PMA-stimulated PLD activation was unaffected [ 171. 
Enhancement of PLD activation by staurosporine has 
been reported in platelet membranes stimulated with 
PMA [18] and in formyl peptide-stimulated human 
Table I 
Inhibition of PKC activity in soluble and particulate fractions derived 
from staurosporine-treated PMNs 
Histone phosphorylation 
(% of controlvalues SD.) 
Staurosporine (nM) Soluble fraction Particulate fraction 
0 (control) 
0 
500 
100% (2425 f 560) 100% (153 & 45) 
100% 14 f 9 
0 0 
PMNs were treated in the absence (control) or presence of 100 and 500 
nM staurosporine for 15 min at 37°C then washed and sonicated. 
Soluble and particulate fractions were separated by ultracentrifuga- 
tion. The calcium- and phospholipid-dependent PKC activity of both 
fractions was assessed in vitro by measuring the incorporation of 
phosphate into histone. Results are expressed as % of control values, 
which are given in brackets in pmol P/min/mg protein. 
Time (min) 
Fig. 2. Time course of phosphatidic acid (PA) and ether-linked 
acylglycerol (EAG) production by staurosporine-treated PMNs. 
PMNs labeled in alkyl-PC were treated in the absence (control) and 
presence of 500 nM staurosporine for various times. Lipids were 
extracted and separated by TLC. PA and EAG production were calcu- 
lated by subtracting the production by control cells from that of cells 
treated with staurosporine. Results are the means of 3 experiments. 
PMNs [19]. These contrasting effects of staurosporine 
would be explained if, in addition to its ability to de- 
press PKC-mediated PLD activation, staurosporine 
promote PLD activation independently of PKC activa- 
tion. This latter possibility is supported here by our 
observation that staurosporine concentrations that 
blocked PKC activation (Table I) induced PLD activa- 
tion (Figs. l-3). Both effects of staurosporine, i.e. stim- 
ulation and inhibition of PLD activation may operate 
to differing extents depending on the cell type, the stim- 
ulant and concentration of staurosporine. PKC-inde- 
pendent mechanisms of enhanced PA production in 
staurosporine-treated PMNs may involve direct activa- 
tion of PLD by staurosporine or indirect effects via 
intermediate components. These possibilities remain to 
be investigated in cell-free systems. Alternatively, stau- 
rosporine may induce PLD activation through the acti- 
vation of uncharacterized kinases [27] or through an 
elevation of cytosolic calcium [28]. PKC inhibitors such 
as sphingoid bases, including sphingosine, have been 
shown to activate of PLD in NG 108-15 cells through 
a mechanism not involving PKC activation [29]. Sphin- 
gosine also inhibits PA hydrolase activity [30]. Activa- 
tion of PLD by sphingosine requires a long aliphatic 
chain and a 2-free amino group, structures not present 
in staurosporine, suggesting that staurosporine and 
sphingosine may enhance PLD activation through dif- 
ferent mechanisms. 
35 
Volume 315, number 1 FEBS LETTERS January 1993 
275 
_+_ PE1 
- PA 
751 
0 200 400 600 800 1000 1200 
Staurosporine (nM) 
Fig. 3. Staurosporine stimulates phosphatidylethanol (PEt) production in PMNs. PMNs labeled in alkyl-PC were treated with 1% ethanol for 3 
min and then incubated in the absence (control) or presence of various staurosporine concentrations for 15 min. PEt and PA productions were 
evaluated after extraction of lipids and separation by TLC. Results are the means of 3 experiments and are expressed as % of control values (927 + 80 
and 2318 + 280 dpm/3 x lo6 PMNs for PEt and PA, respectively). 
The enhancement of PLD activity by staurosporine 
may have some pharmacological consequences. Al- 
though staurosporine is not an endogenous molecule, it 
may be useful for clarifying the mechanism of PLD 
activation and the functional involvement of the PLD 
pathway in cell functions. In human PMNs, PA eleva- 
tion has been correlated [31] and linked [3,4] to simula- 
tion of the respiratory burst. In cell-free systems, PA 
stimulates the production of superoxide anion [32]. The 
significance of PA elevation in staurosporine-treated 
cells is not known, but staurosporine has various acti- 
vating and priming properties. In PMNs, staurosporine 
induces exocytosis [33] and actin polymerization [34] 
and, under certain conditions, potentiates the respira- 
tory burst mediated by chemoattractants [20,35]. In 
other cells, staurosporine promotes changes in mor- 
phology and differentiation similar to those induced by 
phorbol esters [36]. It also mimics nerve growth factor 
for the induction of neuropeptide gene expression [37]. 
Whether or not these cellular responses are due to the 
consequences of PLD activation remains to be exam- 
ined. In addition to its enhancing effect on PLD activa- 
tion, staurosporine may inhibit PA hydrolase, as sug- 
gested by the weak EAG production relative to that of 
PA (Fig. 2). This effect may reduce availability of DAG 
for PKC and thereby may depress PKC activation, in 
addition to its known interfering effect with the ATP 
binding site of PKC (Table I). 
In conclusion, this study provides evidence that stau- 
rosporine concentrations that block PKC activation in- 
duces PLD activation in PMN. Phospholipase D may 
36 
thus represent a potential target for staurosporine ac- 
tion. PLD activation may contribute to the reported 
stimulating properties of staurosporine in various cell 
types. Staurosporine does not appear a very appropri- 
ate probe for investigating the role of PKC in the mech- 
anism of PLD activation but should become an interest- 
ing agent allowing to identify a new step of cell sig- 
nalling. 
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